APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+27.89%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$2.81B
AUM Growth
+$2.81B
(+7.6%)
Cap. Flow
-$74.4M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
33.19%
Holding
104
New
32
Increased
17
Reduced
30
Closed
17
Top Buys
| 1 |
Cigna
CI
|
$67M |
| 2 |
Merck
MRK
|
$66.2M |
| 3 |
CG Oncology
CGON
|
$63.9M |
| 4 |
Illumina
ILMN
|
$63.7M |
| 5 |
Intuitive Surgical
ISRG
|
$56.3M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$84.9M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$65.2M |
| 3 |
Biohaven
BHVN
|
$58.7M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$54.2M |
| 5 |
Zoetis
ZTS
|
$47.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FUSN
1
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $139M | 4.47% | 6,500,328 | – | – |
|
2
Boston Scientific
BSX
$156B
| $134M | 4.32% | 1,956,000 +66,000 | +3% | +$4.52M |
|
3
Arvinas
ARVN
$568M
| $123M | 3.97% | 2,985,190 +73 | +0% | +$3.01K |
|
|
4
Intuitive Surgical
ISRG
$170B
| $90.2M | 2.91% | 226,000 +141,000 | +166% | +$56.3M |
|
5
Dianthus Therapeutics
DNTH
$759M
| $81.5M | 2.63% | 2,717,554 +1,500,000 | +123% | +$45M |
|
6
Acadia Healthcare
ACHC
$2.12B
| $79.6M | 2.57% | 1,005,000 -151,692 | -13% | -$12M |
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $74M | 2.39% | 536,500 -121,500 | -18% | -$16.8M |
|
8
Natera
NTRA
$23.1B
| $73.5M | 2.37% | 803,300 -306,700 | -28% | -$28.1M |
|
9
Jazz Pharmaceuticals
JAZZ
$7.75B
| $70.3M | 2.27% | 584,000 +94,881 | +19% | +$11.4M |
|
10
Avantor
AVTR
$9.18B
| $68.9M | 2.22% | 2,695,000 +573,156 | +27% | +$14.7M |
|
|
11
Cigna
CI
$80.3B
| $67M | 2.16% | +184,500 | New | +$67M |
|
|
12
Merck
MRK
$210B
| $66.2M | 2.14% | +502,000 | New | +$66.2M |
|
13
Regeneron Pharmaceuticals
REGN
$61.5B
| $65.4M | 2.11% | 68,000 | – | – |
|
|
14
CG Oncology
CGON
$2.04B
| $63.9M | 2.06% | +1,454,765 | New | +$63.9M |
|
|
15
Illumina
ILMN
$15.8B
| $63.7M | 2.05% | +464,100 | New | +$63.7M |
|
16
Tenet Healthcare
THC
$16.3B
| $63.2M | 2.04% | 601,000 -270,000 | -31% | -$28.4M |
|
17
Align Technology
ALGN
$10.3B
| $62M | 2% | 189,000 +33,200 | +21% | +$10.9M |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $57.4M | 1.85% | 2,412,500 -1,537,500 | -39% | -$36.6M |
|
19
Eli Lilly
LLY
$657B
| $54.5M | 1.76% | 70,000 -15,000 | -18% | -$11.7M |
|
20
United Therapeutics
UTHR
$13.8B
| $49.8M | 1.61% | 217,000 -20,202 | -9% | -$4.64M |
|
|
ALPN
21
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $46.6M | 1.5% | +1,174,700 | New | +$46.6M |
|
22
Ultragenyx Pharmaceutical
RARE
$2.89B
| $43.6M | 1.41% | 933,500 +89,000 | +11% | +$4.16M |
|
23
CVS Health
CVS
$92.8B
| $43.5M | 1.4% | 545,000 -195,000 | -26% | -$15.6M |
|
24
Surgery Partners
SGRY
$2.91B
| $43.1M | 1.39% | 1,445,000 +279,068 | +24% | +$8.32M |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $41.5M | 1.34% | 600,000 -110,000 | -15% | -$7.61M |
|